FDA Accepts BLA for Ozekibart in Chondrosarcoma, Sets April 2027 PDUFA Date
INBX has more than doubled off its 52-week low of $13.97.
Summary
The FDA has accepted Inhibrx Biosciences' BLA for ozekibart for chondrosarcoma, setting an April 14, 2027 PDUFA goal date and identifying no filing review issues.
Key Events · Product Development and Regulatory · INBX
-
FDA Accepts BLA for Ozekibart
The U.S. Food and Drug Administration (FDA) has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) for the treatment of unresectable or metastatic conventional chondrosarcoma.
-
PDUFA Goal Date Set
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027, for a decision on ozekibart.
-
No Filing Review Issues Identified
The FDA has not identified any filing review issues at this time, indicating a smooth progression of the application review process.
-
Potential First-in-Class Therapy
If approved, ozekibart would be the first FDA-approved systemic therapeutic for patients with unresectable or metastatic conventional chondrosarcoma, addressing a significant unmet medical need.
Analysis · INBX · Life Sciences
The FDA's acceptance of the Biologics License Application (BLA) for ozekibart is a critical step towards commercialization. This confirms the application is complete and under active review, moving the drug closer to potential approval. Ozekibart targets a rare and aggressive bone cancer with no approved therapies, making its potential approval a significant event for both patients and the company, establishing a clear timeline for a regulatory decision.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.8% of the 985 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBX was trading at $93.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $13.97 to $155.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.